-
Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-11
Background The prevalence of type 2 diabetes is increasing rapidly, particularly among younger age groups. Estimates suggest that people with diabetes die, on average, 6 years earlier than people without diabetes. We aimed to provide reliable estimates of the associations between age at diagnosis of diabetes and all-cause mortality, cause-specific mortality, and reductions in life expectancy. Methods
-
Current insights and emerging trends in early-onset type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-11 Shivani Misra, Calvin Ke, Shylaja Srinivasan, Alpesh Goyal, Moffat J Nyriyenda, Jose C Florez, Kamlesh Khunti, Dianna J Magliano, Andrea Luk
Type 2 diabetes diagnosed in childhood or early adulthood is termed early-onset type 2 diabetes. Cases of early-onset type 2 diabetes are increasing rapidly globally, alongside rising obesity. Compared with a diagnosis later in life, an earlier-onset diagnosis carries an unexplained excess risk of microvascular complications, adverse cardiovascular outcomes, and earlier death. Women with early-onset
-
Many years of life lost to young-onset type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-11 Bruce B Duncan, Maria Inês Schmidt
Abstract not available
-
The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-08 Yanning Xu, Arash Derakhshan, Ola Hysaj, Lea Wildisen, Till Ittermann, Alessandro Pingitore, Nazanin Abolhassani, Marco Medici, Lambertus A L M Kiemeney, Niels P Riksen, Robin P F Dullaart, Stella Trompet, Marcus Dörr, Suzanne J Brown, Börge Schmidt, Dagmar Führer-Sakel, Mark P J Vanderpump, Axel Muendlein, Heinz Drexel, Howard A Fink, Layal Chaker
Background Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are statistically defined by the 2·5–97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease and mortality. Methods This systematic review and individual participant data (IPD) meta-analysis
-
Is it time to re-assess the development of thyroid function reference ranges? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-08 Elizabeth N Pearce
Abstract not available
-
Craniopharyngioma: medico-social support for optimised care Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-06 Thomas Cuny, Rachel Reynaud, Pascal Barat, Blandine Gatta-Cherifi
Abstract not available
-
Maternal type 1 diabetes and relative protection against offspring transmission Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-09-01 Lowri A Allen, Peter N Taylor, Kathleen M Gillespie, Richard A Oram, Colin M Dayan
Type 1 diabetes is around twice as common in the offspring of men with type 1 diabetes than in the offspring of women with type 1 diabetes, but the reasons for this difference are unclear. This Review summarises the evidence on the rate of transmission of type 1 diabetes to the offspring of affected fathers compared with affected mothers. The findings of nine major studies are presented, describing
-
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-31 Bradley D Anawalt
Abstract not available
-
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-28 Lia Bally, Bernard Khoo, Filip Knop, Sten Madsbad, Mary-Elizabeth Patti, Tricia Tan
Abstract not available
-
Built environment and obesity prevention research: moving from niche to norm Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-22 Deborah Salvo, Maura Kepper, Ruth Hunter, Alejandra Jáuregui
Abstract not available
-
Tuning of cellular insulin release by music for real-time diabetes control Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-22 Haijie Zhao, Shuai Xue, Marie-Didiée Hussherr, Peter Buchmann, Ana Palma Teixeira, Martin Fussenegger
Abstract not available
-
Carmella Evans-Molina: being of service Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-22 Talha Burki
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-22
Abstract not available
-
Good news for patients with adrenocortical carcinoma from the ADIUVO trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-21 Martin Reincke
Abstract not available
-
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-21 Massimo Terzolo, Martin Fassnacht, Paola Perotti, Rossella Libé, Darko Kastelan, André Lacroix, Wiebke Arlt, Harm Reinout Haak, Paola Loli, Bénédicte Decoudier, Helene Lasolle, Marcus Quinkler, Magalie Haissaguerre, Olivier Chabre, Philippe Caron, Antonio Stigliano, Roberta Giordano, Maria Chiara Zatelli, Irina Bancos, Maria Candida Barisson Villares Fragoso, Alfredo Berruti
Background Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate
-
Eating disorders: care not keeping up with demand Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-10
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 490–508 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-07
Abstract not available
-
National UK guidelines for the management of paediatric craniopharyngioma Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-08-04 Hoong-Wei Gan, Paul Morillon, Assunta Albanese, Kristian Aquilina, Chris Chandler, Yen-Ching Chang, Evangelos Drimtzias, Sarah Farndon, Thomas S Jacques, Márta Korbonits, Adam Kuczynski, Jennifer Limond, Louise Robinson, Ian Simmons, Nick Thomas, Sophie Thomas, Nicola Thorp, Faraneh Vargha-Khadem, Daniel Warren, Bassel Zebian, Helen Alexandra Spoudeas
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic–pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To
-
Achieving replicable subphenotypes of adult-onset diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-31 Jithin Sam Varghese, Rodrigo M Carrillo-Larco, KM Venkat Narayan
Abstract not available
-
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-31 Norbert Stefan, Matthias B Schulze
Abstract not available
-
Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-28 Nikolaos Perakakis, Hani Harb, Benjamin G Hale, Zsuzsanna Varga, Charlotte Steenblock, Waldemar Kanczkowski, Vasileia Ismini Alexaki, Barbara Ludwig, Peter Mirtschink, Michele Solimena, Nicole Toepfner, Sebastian Zeissig, Manuel Gado, Irene Alma Abela, Felix Beuschlein, Giatgen A Spinas, Claudia Cavelti-Weder, Philipp A Gerber, Michael Huber, Alexandra Trkola, Stefan R Bornstein
Viruses have been present during all evolutionary steps on earth and have had a major effect on human history. Viral infections are still among the leading causes of death. Another public health concern is the increase of non-communicable metabolic diseases in the last four decades. In this Review, we revisit the scientific evidence supporting the presence of a strong bidirectional feedback loop between
-
There is no magic bullet for obesity Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-25 Ildiko Lingvay, Priya Sumithran, Carel W le Roux, Ricardo V Cohen
Abstract not available
-
Addressing health and demographic challenges in Japan's ageing society Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-25 Eri Toda Kato, Junko Sato
Abstract not available
-
Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-24 André J Scheen
Abstract not available
-
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-24 Yan Xie, Benjamin Bowe, Hong Xian, Travis Loux, Janet B McGill, Ziyad Al-Aly
Background Randomised clinical trials showed that compared with placebo, SGLT2 inhibitors and GLP-1 receptor agonists reduced risk of adverse cardiovascular events. The evidence base for the older antihyperglycaemic drug classes (DPP-4 inhibitors and sulfonylureas) is generally less well developed. Because most randomised trials evaluated one antihyperglycaemic medication versus placebo, a head-to-head
-
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-21 Lotte M de Boer, Albert Wiegman, Jeffrey Kroon, Sotirios Tsimikas, Calvin Yeang, Merel C Peletier, Alma Revers, John J P Kastelein, Aeilko H Zwinderman, Barbara A Hutten
Background Elevated lipoprotein(a) and familial hypercholesterolaemia are both independent risk conditions for cardiovascular disease. Although signs of atherosclerosis can be observed in children with familial hypercholesterolaemia, it is unknown whether elevated lipoprotein(a) is an additional risk factor for atherosclerosis in these young patients. Therefore, we aimed to assess the contribution
-
Lipoprotein(a) and subclinical vascular disease progression in children with familial hypercholesterolaemia Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-21 Raul D Santos
Abstract not available
-
Increased cardiovascular morbidity and mortality in patients with resistance to thyroid hormone Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-17 Samuel Refetoff, Luca Persani, W Edward Visser
Abstract not available
-
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-17 Onyebuchi E Okosieme, Danyal Usman, Peter N Taylor, Colin M Dayan, Greta Lyons, Carla Moran, Krishna Chatterjee, Dafydd Aled Rees
Background Individuals with resistance to thyroid hormone owing to mutations in the thyroid hormone receptor β gene (RTHβ) exhibit impaired tissue sensitivity to thyroid hormones, but retain sensitivity in cardiac tissue. Long-term health and survival outcomes in this rare disorder have not been evaluated. We investigated all-cause mortality and cardiovascular event risk in a cohort of patients with
-
Obesity in the USA: diet and lifestyle key to prevention Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-14 Frank B Hu
Abstract not available
-
Expression of Concern—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-13
Abstract not available
-
Peerzada Ovais Ahmad: a quest to save lives Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-12 Apoorva Gomber, Marta Koch
Abstract not available
-
Banning diabetes blanket bans Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-12
Abstract not available
-
Gender equality: timely and timeless Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-11
Abstract not available
-
Diagnostic challenges in cyclic Cushing's syndrome: a systematic review Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-07 Elisabeth Nowak, Frederick Vogel, Adriana Albani, Leah Braun, German Rubinstein, Stephanie Zopp, Katrin Ritzel, Felix Beuschlein, Marily Theodoropoulou, Martin Reincke
Cyclic Cushing's syndrome is a subentity of Cushing's syndrome in which phases of biochemical hypercortisolism (peaks) are followed by spontaneous periods of physiological or even hypocortisolaemic cortisol secretion (troughs). To identify common features of cyclic Cushing's syndrome, we systematically reviewed single case reports and case series in MEDLINE from database inception to Oct 10, 2022,
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 86–95 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-05
Abstract not available
-
Prediabetes: never too early to intervene Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-03 Clifford J Bailey
Abstract not available
-
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-03 Lihui Zhang, Yunliang Zhang, Sheng'ai Shen, Xueying Wang, Luling Dong, Qiuyun Li, Weidong Ren, Yufeng Li, Jianling Bai, Qiuhong Gong, Hongyu Kuang, Lin Qi, Qiang Lu, Wenli Cheng, Yanjie Liu, Shuang Yan, Donghong Wu, Hui Fang, Fang Hou, Yingju Wang, Qiuhong Gong
Background Impaired glucose regulation (defined as either impaired glucose tolerance or impaired fasting glucose) is an important risk factor for the development of diabetes. We aimed to evaluate the safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing diabetes in Chinese participants with impaired glucose regulation. Methods We
-
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-03 Marius Svanevik, Jolanta Lorentzen, Heidi Borgeraas, Rune Sandbu, Birgitte Seip, Asle W Medhus, Jens K Hertel, Ronette L Kolotkin, Milada C Småstuen, Dag Hofsø, Jøran Hjelmesæth
Background Little is known about the comparative effects of various bariatric procedures on patient-reported outcomes. We aimed to compare 3-year effects of gastric bypass and sleeve gastrectomy on patient-reported outcome measures in patients with obesity and type 2 diabetes. Methods The Oseberg trial was a single-centre, parallel-group, randomised trial at Vestfold Hospital Trust, a public tertiary
-
Patient-reported outcome measures after metabolic surgery Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-07-03 Geltrude Mingrone, Lidia Castagneto-Gissey, Stefan R Bornstein
Abstract not available
-
Islet autoimmunity and type 1 diabetes associated with enterovirus infections Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-27 Antonio Toniolo
Abstract not available
-
Sleep and cardiometabolic health—not so strange bedfellows Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-27 Shahrad Taheri
Abstract not available
-
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-27 Sonia R Isaacs, Anju Roy, Brieana Dance, Emily J Ward, Dylan B Foskett, Anna J Maxwell, William D Rawlinson, Ki Wook Kim, Maria E Craig
Background Enteroviruses are routinely detected with molecular methods within large cohorts that are at risk of type 1 diabetes. We aimed to examine the association between enteroviruses and either islet autoimmunity or type 1 diabetes. Methods For this systematic review and meta-analysis, we searched PubMed and Embase for controlled observational studies from inception until Jan 1, 2023. Cohort or
-
Predicting and preventing heart failure in type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-26 Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V Patel, Deepak L Bhatt, Subodh Verma
The burden of heart failure among people with type 2 diabetes is increasing globally. People with comorbid type 2 diabetes and heart failure often have worse outcomes than those with only one of these conditions—eg, higher hospitalisation and mortality rates. Therefore, it is essential to implement optimal heart failure prevention strategies for people with type 2 diabetes. A detailed understanding
-
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-26 Ravikumar Balasubramanian
Abstract not available
-
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-26 Ana P M Canton, Flávia R Tinano, Leonardo Guasti, Luciana R Montenegro, Fiona Ryan, Deborah Shears, Maria Edna de Melo, Larissa G Gomes, Mariana P Piana, Raja Brauner, Rafael Espino-Aguilar, Arancha Escribano-Muñoz, Alyssa Paganoni, Jordan E Read, Márta Korbonits, Carlos E Seraphim, Silvia S Costa, Ana Cristina Krepischi, Alexander A L Jorge, Alessia David, Ana Claudia Latronico
Background Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several
-
Managing type 2 diabetes needs a paradigm change Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-26 K M Venkat Narayan, Ram Jagannathan, Martin Ridderstråle
Abstract not available
-
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-23 Hiddo JL Heerspink, David ZI Cherney, Per-Henrik Groop, Chantal Matthieu, Peter Rossing, Katherine R Tuttle, Janet B McGill
Abstract not available
-
Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-22 Saria Hassan, Unjali P Gujral, Rakale C Quarells, Elizabeth C Rhodes, Megha K Shah, Jane Obi, Wei-Hsuan Lee, Luwi Shamambo, Mary Beth Weber, K M Venkat Narayan
Type 2 diabetes disparities in the USA persist in both the prevalence of disease and diabetes-related complications. We conducted a literature review related to diabetes prevention, management, and complications across racial and ethnic groups in the USA. The objective of this review is to summarise the current understanding of diabetes disparities by examining differences between and within racial
-
Diabetes care and AI: a looming threat or a necessary advancement? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-15
Abstract not available
-
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17) Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-07 Ranjit Mohan Anjana, Ranjit Unnikrishnan, Mohan Deepa, Rajendra Pradeepa, Nikhil Tandon, Ashok Kumar Das, Shashank Joshi, Sarita Bajaj, Puthiyaveettil Kottayam Jabbar, Hiranya Kumar Das, Ajay Kumar, Vinay Kumar Dhandhania, Anil Bhansali, Paturi Vishnupriya Rao, Ankush Desai, Sanjay Kalra, Arvind Gupta, Ramakrishnan Lakshmy, Sri Venkata Madhu, Nirmal Elangovan, Sujoy Ghosh
Background Non-communicable disease (NCD) rates are rapidly increasing in India with wide regional variations. We aimed to quantify the prevalence of metabolic NCDs in India and analyse interstate and inter-regional variations. Methods The Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, a cross-sectional population-based survey, assessed a representative sample of individuals
-
Cardiometabolic risk factor prevalence in a representative population of adults in India Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-07 Sarah Wild
Abstract not available
-
Importance of residual insulin secretion in type 1 diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-05 Jay S Skyler
Abstract not available
-
Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-05 Katrien Benhalima, Kaat Beunen, Sarah E Siegelaar, Rebecca Painter, Helen R Murphy, Denice S Feig, Lois E Donovan, Sarit Polsky, Elizabeth Buschur, Carol J Levy, Yogish C Kudva, Tadej Battelino, Lene Ringholm, Elisabeth R Mathiesen, Chantal Mathieu
Glucose concentrations within target, appropriate gestational weight gain, adequate lifestyle, and, if necessary, antihypertensive treatment and low-dose aspirin reduces the risk of pre-eclampsia, preterm delivery, and other adverse pregnancy and neonatal outcomes in pregnancies complicated by type 1 diabetes. Despite the increasing use of diabetes technology (ie, continuous glucose monitoring and
-
Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-05 Minna Harsunen, Jani Haukka, Valma Harjutsalo, Nina Mars, Anna Syreeni, Taina Härkönen, Annemari Käräjämäki, Jorma Ilonen, Mikael Knip, Niina Sandholm, Päivi Johanna Miettinen, Per-Henrik Groop, Tiinamaija Tuomi
Background Contrary to the presumption that type 1 diabetes leads to an absolute insulin deficiency, many individuals with type 1 diabetes have circulating C-peptide years after the diagnosis. We studied factors affecting random serum C-peptide concentration in individuals with type 1 diabetes and the association with diabetic complications. Methods Our longitudinal analysis included individuals newly
-
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-02 Dariush Mozaffarian
Abstract not available
-
Vin Tangpricha: advocating evidence-based transgender care Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-06-01 Talha Burki
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 414–25 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-05-29
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 75–76 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-05-24
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2022; 10: 720–31 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-05-24
Abstract not available